S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The 3-Stock Retirement Blueprint (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The 3-Stock Retirement Blueprint (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The 3-Stock Retirement Blueprint (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The 3-Stock Retirement Blueprint (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
OTCMKTS:BRTX

BioRestorative Therapies - BRTX Stock Forecast, Price & News

$3.23
+0.25 (+8.39%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.98
$3.39
50-Day Range
$2.46
$3.40
52-Week Range
$2.46
$24.00
Volume
59,387 shs
Average Volume
15,577 shs
Market Capitalization
$11.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.00

BioRestorative Therapies MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,045.5% Upside
$37.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.90mentions of BioRestorative Therapies in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$24,258 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.14) to ($2.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

BRTX stock logo

About BioRestorative Therapies (OTCMKTS:BRTX) Stock

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.

Receive BRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter.

BRTX Stock News Headlines

Best Online Therapy Of 2022
Major Catalyst Near Term
BioRestorative Therapies, Inc. (BRTX)
See More Headlines
Receive BRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter.

BRTX Company Calendar

Last Earnings
8/15/2022
Today
10/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BRTX
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$37.00
High Stock Price Forecast
$37.00
Low Stock Price Forecast
$37.00
Forecasted Upside/Downside
+1,045.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-44,300,000.00
Net Margins
-34,060.00%
Pretax Margin
-34,078.00%

Debt

Sales & Book Value

Annual Sales
$50,000.00
Book Value
$6.18 per share

Miscellaneous

Free Float
2,645,000
Market Cap
$11.79 million
Optionable
Not Optionable
Beta
70.52

Key Executives

  • Mr. Lance AlstodtMr. Lance Alstodt (Age 51)
    Chairman, Pres & CEO
    Comp: $275k
  • Mr. Francisco J. Silva (Age 47)
    Chief Scientist, VP of R&D, Sec. and Director
    Comp: $259.38k
  • Mr. Robert Eugene Kristal (Age 54)
    Chief Financial Officer
  • Mr. Robert Paccasassi (Age 53)
    VP of Quality Assurance & Regulatory Compliance
  • Dr. Wayne J. Olan M.D.
    Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board













BRTX Stock - Frequently Asked Questions

Should I buy or sell BioRestorative Therapies stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioRestorative Therapies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BRTX shares.
View BRTX analyst ratings
or view top-rated stocks.

What is BioRestorative Therapies' stock price forecast for 2022?

2 Wall Street research analysts have issued 12 month price targets for BioRestorative Therapies' shares. Their BRTX share price forecasts range from $37.00 to $37.00. On average, they expect the company's stock price to reach $37.00 in the next year. This suggests a possible upside of 1,045.5% from the stock's current price.
View analysts price targets for BRTX
or view top-rated stocks among Wall Street analysts.

How have BRTX shares performed in 2022?

BioRestorative Therapies' stock was trading at $4.34 on January 1st, 2022. Since then, BRTX shares have decreased by 25.6% and is now trading at $3.23.
View the best growth stocks for 2022 here
.

How were BioRestorative Therapies' earnings last quarter?

BioRestorative Therapies, Inc. (OTCMKTS:BRTX) issued its quarterly earnings results on Monday, August, 15th. The company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($0.55) by $0.73. The firm earned $0.07 million during the quarter. BioRestorative Therapies had a negative net margin of 34,060.00% and a negative trailing twelve-month return on equity of 245.85%.

When did BioRestorative Therapies' stock split?

Shares of BioRestorative Therapies reverse split on the morning of Wednesday, October 27th 2021. The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

What other stocks do shareholders of BioRestorative Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioRestorative Therapies investors own include Co-Diagnostics (CODX), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), iBio (IBIO), Inovio Pharmaceuticals (INO), PharmaCyte Biotech (PMCB), Vaxart (VXRT), Actinium Pharmaceuticals (ATNM), Inpixon (INPX) and OPKO Health (OPK).

What is BioRestorative Therapies' stock symbol?

BioRestorative Therapies trades on the OTCMKTS under the ticker symbol "BRTX."

How do I buy shares of BioRestorative Therapies?

Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioRestorative Therapies' stock price today?

One share of BRTX stock can currently be purchased for approximately $3.23.

How much money does BioRestorative Therapies make?

BioRestorative Therapies (OTCMKTS:BRTX) has a market capitalization of $11.79 million and generates $50,000.00 in revenue each year.

How can I contact BioRestorative Therapies?

BioRestorative Therapies' mailing address is 40 MARCUS DRIVE, MELVILLE NY, 11747. The official website for the company is www.biorestorative.com. The company can be reached via phone at (631) 760-8100 or via email at ir@biorestorative.com.

This page (OTCMKTS:BRTX) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.